- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01939145
Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation
A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overview This is a prospective, randomized, comparative trial examining 2 different instillation solutions for NPWTi. All wound types that meet the eligibility criteria will be enrolled into the study. After enrollment, subjects will be randomized into either the Prontosan NPWTi group (n=50) or the normal saline NPWTi group (n=50). Data will be collected from inpatient hospital records.
Outline of Study Procedures
- Patients meeting the eligibility criteria requiring hospital admission for an infected wound will be identified. Demographic information will be obtained.
- Informed consent will be obtained.
- Subjects will be taken to the operating room for wound debridement within 72 hours of admission per standard of care (SOC). Further, antibiotic therapy and medical management will be performed per SOC.
- Randomization into the Prontosan or normal saline instillation group will be conducted after the informed consent has been signed, but before the first operation.
For the first operating room visit the following will be conducted:
- Pre- and post debridement qualitative cultures
- Debridement performed in SOC fashion
- Post debridement measurements
- Application of NPWTi
For subsequent operating room visits the following will be conducted:
a. Pre- and post debridement qualitative cultures b. Debridement performed in SOC fashion c. Post debridement measurements d. Application of NPWTi or closure i. The decision to close the wound will be determined by the clinician per SOC.
ii. The technique utilized for closure will be determined by the clinician per SOC.
Subjects will discharged from the hospital
a. Criteria for discharge will be per the judgment of the investigator per SOC
- After hospital discharge, the subject will be followed in the outpatient wound clinic per SOC. Information from the one month follow-up period will be collected. Subjects will be exited from the study at that point.
Subject Recruitment No active recruitment strategy will be employed. Patients who meet the eligibility criteria will be approached to participate into the study.
Participation Completion and Discontinuation:
Subjects may elect to discontinue participation at any time for any reason. Investigators may elect to remove the subject from participating at any time for any reason.
Surgical Technique:
Surgical debridement will be performed in SOC manner and is at the discretion of the investigator.
Postoperative Care:
Will be conducted in customary SOC fashion and is at the discretion of the investigator. The 30 day follow-up visit is part of SOC
Application of Devices/Dressing:
The device that will be utilized is the V.A.C. Ulta with Veraflo Technology (Kinetic Concepts Inc., San Antonio, TX). This is an FDA approved device that is indicated for wound care. The investigators currently use this device as the SOC for the inpatient management of the acutely infected wound. The device consists of a foam sponge applied to the wound surface with an adhesive drape that keeps it in place. This device applies subatmospheric pressure at -125mmHg to the wound surface. The instillation component includes the delivery of a topical solution at prescribed fashion to the wound surface. This solution is dwelled (no negative pressure during this interval) in the sponge for a specific duration and then is evacuated.
Negative Pressure Wound Therapy:
The setting for negative pressure will be -125mmHg, continuous setting, and moderate intensity. The application of the foam and drape will be conducted in the customary fashion. The negative pressure duration will be 2 hours.
Prontosan:
Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
Normal Saline:
Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Medstar Georgetown University Hospital Center for Wound Healing
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female greater than 18 years of age
- Admission to the hospital for an infected wound
- Diabetic, ischemic, neuropathic, venous, surgical wounds, any anatomical location
- Subjects requiring serial (more than 1) operative debridement
Exclusion Criteria:
- Pregnancy
- Patients with exposed bowel, brain matter, spinal cord
- Patients with exposed peripheral bypass grafts
- Known allergy or sensitivity to Prontosan or components of NPWT
- Known allergy or sensitivity to adhesives
- Uncontrolled bleeding disorders/coagulopathy
- Wounds that tunnel to unexposed areas
- Malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Normal Saline
The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
|
Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation.
This solution has high tolerability.
Normal saline has been used as the instillation solution for NPWTi.
The dwell setting for this solution is 20 minutes.
The volume of solution to be used is dependent on the size of the wound hence varies
Other Names:
|
Active Comparator: Prontosan
The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
|
Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water.
The polyhexanide is an antiseptic and betaine is a surfactant.
This solution is an FDA approved device indicated for topical irrigation.
This solution has high tolerability with robust antimicrobial activity.
Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results.
Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC.
The dwell setting for this solution is 20 minutes.
The volume of solution to be used is dependent on the size of the wound hence varies.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Operating Room Visits
Time Frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Compare the number of operative room visits between Prontosan NPWTi and normal saline NPWTi.
|
Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Admission Length of Stay
Time Frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Compare the hospital admission length of stay between Prontosan NPWTi and normal saline NPWTi.
|
Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Closure
Time Frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Compare the percent of wounds closed and the time to closure during the hospital admission and up to one year after discharge between Prontosan NPWTi and normal saline NPWTi.
|
Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Wound Recidivism
Time Frame: 30 days post discharge from hospital
|
Compare the percent of wounds that remained closed 30 days and up to one year after discharge between Prontosan NPWTi and normal saline NPWTi.
|
30 days post discharge from hospital
|
Bacterial Culture Results
Time Frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Compare the qualitative bacterial culture results between Prontosan NPWTi and normal saline NPWTi.
|
Patients will be followed during their hospital stay which is an average of approximately 2 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christopher Attinger, MD, MedStar Georgetown University Hospital
- Study Director: Paul Kim, DPM, MedStar Georgetown University Hospital
- Principal Investigator: John Steinberg, DPM, MedStar Georgetown University Hospital
- Principal Investigator: Karen Evans, MD, MedStar Georgetown University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06142013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound Infection
-
Pulmatrix Inc.TerminatedPost Operative Wound Infection | Postoperative Wound Infection-deepUnited States
-
Carilion ClinicSmith & Nephew, Inc.; DeRoyal Industries, Inc.CompletedImpaired Wound Healing | Postoperative Wound Infection-deepUnited States
-
PolyPid Ltd.CompletedPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical SiteIsrael
-
Children's Healthcare of AtlantaWithdrawnPostoperative Wound InfectionUnited States
-
HITEC-Institute of Medical SciencesCompletedWound Infection | Wound Dehiscence | Wound Surgical | Wound BleedingPakistan
-
Universitat Internacional de CatalunyaHospital de GranollersCompletedSurgical Wound Infection | Postoperative Wound Infection | Postoperative Wound Infection Superficial Incisional | Preventive TherapySpain
-
PfizerCompletedSurgical Wound Infection | Postoperative Wound Infection
-
Military Medical AcademyRecruitingPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical SiteBulgaria
-
Hospital for Special Surgery, New YorkNew York Presbyterian HospitalRecruitingSurgical Wound | Post Operative Wound InfectionUnited States
-
Brentwood Biomedical Research InstituteCompletedPostoperative Wound Infection | Traumatic Wound Infection | Closed Soft Tissue AbscessUnited States
Clinical Trials on Normal saline
-
Texas Cardiac Arrhythmia Research FoundationSuspendedVentricular ArrythmiaUnited States
-
The Catholic University of KoreaCompleted
-
Texas Cardiac Arrhythmia Research FoundationCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
MemorialCare Health SystemCompletedLength of Labor | Second Stage of Labor | Intravenous Hydration of LaborUnited States
-
University of HaifaWestern Galilee Hospital-NahariyaRecruiting
-
McMaster UniversityGlaxoSmithKline; University of ManchesterRecruitingAsthma | Eosinophilic Bronchitis | Chronic CoughCanada
-
University of MichiganRadiological Society of North AmericaTerminated
-
Virginia Commonwealth UniversityUnited States Department of DefenseWithdrawn
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia